B M Paterson
- The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept studyB M Paterson
Alba Therapeutics Corporation, Baltimore, MD 21201, USA
Aliment Pharmacol Ther 26:757-66. 2007..AT-1001 is an inhibitor of paracellular permeability whose structure is derived from a protein secreted by Vibrio cholerae...
- Oral Formulation of Zonulin Antagonist AT-1001 for DiabeBLAKE PATERSON; Fiscal Year: 2006..To develop bioanalytical methods for measuring AT1001 and its physiologic effect AIM 3. To perform Pharmacodynamic and Pharmacokinetic Studies with AT100 AIM 4. Develop optimal oral formulations for AT-1001 [unreadable] [unreadable]..